Physician profile
Max Steven Pitman
NPI 1932466026
$2,242.68
in general payments reported to CMS, 2019-2025
15 companies · $841 in 2025
The $841 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $41.97 · 2021: $50.39 · 2022: $12.70 · 2023: $83.67 · 2024: $817 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $920.03 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $363.37 | 2019-2025 | Entyvio |
| Allergan, INC. | $148.69 | 2019 | |
| Phathom Pharmaceuticals, INC. | $141.76 | 2024 | Voquezna |
| Covidien LP | $125.00 | 2019 | |
| Lilly USA, LLC | $120.25 | 2025 | Omvoh |
| Pfizer INC. | $90.99 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.02 | 2021-2024 | Xifaxan |
| Celgene Corporation | $63.40 | 2023-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $59.39 | 2024 | Dificid |
| Braintree Laboratories, INC. | $46.20 | 2019-2020 | |
| Genzyme Corporation | $45.42 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $20.18 | 2024 | Dupixent |
| Qol Medical, LLC | $17.28 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Max Pitman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.